注册 | 登录
所有产品
  • 所有产品
  • 一抗
  • 裂解液
>   首页   >   产品   >   一抗   >   癌症   >   MDM2 Antibody   

MDM2 Antibody

Purified Mouse Monoclonal Antibody (Mab)

     
标注"皇冠"的产品,是满足高质量标准的产品。
了解更多...
  • 1 - MDM2 Antibody AM8613b
    Anti-MDM2 Antibody at 1:4000 dilution + MCF-7 whole cell lysate Lysates/proteins at 20 µg per lane. Secondary Goat Anti-mouse IgG, (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 55 kDa Blocking/Dilution buffer: 5% NFDM/TBST.
  • 产品详情
  • 实验流程
  • 背景知识
Product info
Application
  • Applications Legend:
  • E=ELISA
  • WB=Western Blotting
  • IHC=Immunohistochemistry
  • IHC-P=Immunohistochemistry (Paraffin)
  • IP=Immunoprecipitation
  • IF=Immunofluorescence
  • IC=Immunochemistry
  • ICC=Immunocytochemistry
  • FC=Flow Cytometry
  • DB=Dot Blot
WB, E
Primary Accession Q00987
Reactivity Human
Host Mouse
Clonality monoclonal
Isotype IgG1,k
Clone Names 1806CT309.52.1
Calculated MW 55233 Da
Additional info
Gene ID 4193
Other Names E3 ubiquitin-protein ligase Mdm2, 6.3.2.-, Double minute 2 protein, Hdm2, Oncoprotein Mdm2, p53-binding protein Mdm2, MDM2
Target/Specificity This MDM2 antibody is generated from a mouse immunized with a recombinant protein between 196-435 amino acids from the human MDM2.
Dilution WB~~1:4000
StorageMaintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
PrecautionsMDM2 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.
Protein Information
Name MDM2
Function E3 ubiquitin-protein ligase that mediates ubiquitination of p53/TP53, leading to its degradation by the proteasome. Inhibits p53/TP53- and p73/TP73-mediated cell cycle arrest and apoptosis by binding its transcriptional activation domain. Also acts as a ubiquitin ligase E3 toward itself and ARRB1. Permits the nuclear export of p53/TP53. Promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma RB1 protein. Inhibits DAXX-mediated apoptosis by inducing its ubiquitination and degradation. Component of the TRIM28/KAP1-MDM2-p53/TP53 complex involved in stabilizing p53/TP53. Also component of the TRIM28/KAP1-ERBB4-MDM2 complex which links growth factor and DNA damage response pathways. Mediates ubiquitination and subsequent proteasome degradation of DYRK2 in nucleus. Ubiquitinates IGF1R and SNAI1 and promotes them to proteasomal degradation.
Cellular Location Nucleus, nucleoplasm. Cytoplasm. Nucleus, nucleolus. Note=Expressed predominantly in the nucleoplasm Interaction with ARF(P14) results in the localization of both proteins to the nucleolus. The nucleolar localization signals in both ARF(P14) and MDM2 may be necessary to allow efficient nucleolar localization of both proteins. Colocalizes with RASSF1 isoform A in the nucleus
Tissue Location Ubiquitous. Isoform Mdm2-A, isoform Mdm2-B, isoform Mdm2-C, isoform Mdm2-D, isoform Mdm2-E, isoform Mdm2-F and isoform Mdm2-G are observed in a range of cancers but absent in normal tissues
Research Areas

BACKGROUND

E3 ubiquitin-protein ligase that mediates ubiquitination of p53/TP53, leading to its degradation by the proteasome. Inhibits p53/TP53- and p73/TP73-mediated cell cycle arrest and apoptosis by binding its transcriptional activation domain. Also acts as a ubiquitin ligase E3 toward itself and ARRB1. Permits the nuclear export of p53/TP53. Promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma RB1 protein. Inhibits DAXX-mediated apoptosis by inducing its ubiquitination and degradation. Component of the TRIM28/KAP1-MDM2-p53/TP53 complex involved in stabilizing p53/TP53. Also component of the TRIM28/KAP1-ERBB4-MDM2 complex which links growth factor and DNA damage response pathways. Mediates ubiquitination and subsequent proteasome degradation of DYRK2 in nucleus. Ubiquitinates IGF1R and SNAI1 and promotes them to proteasomal degradation.

REFERENCES

Oliner J.D.,et al.Nature 358:80-83(1992).
Sigalas I.,et al.Nat. Med. 2:912-917(1996).
Veldhoen N.,et al.Oncogene 18:7026-7033(1999).
Tamborini E.,et al.Int. J. Cancer 92:790-796(2001).
Ota T.,et al.Nat. Genet. 36:40-45(2004).

FeedBack

终于等到您。感谢您使用ABGENT(百奇生物)抗体产品。
点击下方“我要评价 ”按钮提交您的反馈信息,您的反馈和评价是我们最宝贵的财富之一,
我们将在1-3个工作日内处理您的反馈信息。

如有疑问,联系:0512-69552906 tech.abgent@wuxiapptec.com.


我要评价